DK3444274T3 - Stabile og opløselige antistoffer, der hæmmer TNF - Google Patents
Stabile og opløselige antistoffer, der hæmmer TNF Download PDFInfo
- Publication number
- DK3444274T3 DK3444274T3 DK18177227.8T DK18177227T DK3444274T3 DK 3444274 T3 DK3444274 T3 DK 3444274T3 DK 18177227 T DK18177227 T DK 18177227T DK 3444274 T3 DK3444274 T3 DK 3444274T3
- Authority
- DK
- Denmark
- Prior art keywords
- stable
- inhibit tnf
- soluble antibodies
- antibodies
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7564008P | 2008-06-25 | 2008-06-25 | |
US7569208P | 2008-06-25 | 2008-06-25 | |
US7569708P | 2008-06-25 | 2008-06-25 | |
US7595608P | 2008-06-26 | 2008-06-26 | |
US15504109P | 2009-02-24 | 2009-02-24 | |
EP09768692.7A EP2307457B2 (en) | 2008-06-25 | 2009-06-25 | Stable and soluble antibodies inhibiting tnf |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3444274T3 true DK3444274T3 (da) | 2021-03-22 |
Family
ID=41100661
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09768692.7T DK2307457T4 (da) | 2008-06-25 | 2009-06-25 | Stabile og opløselige tnf-hæmmende antistoffer |
DK18177227.8T DK3444274T3 (da) | 2008-06-25 | 2009-06-25 | Stabile og opløselige antistoffer, der hæmmer TNF |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09768692.7T DK2307457T4 (da) | 2008-06-25 | 2009-06-25 | Stabile og opløselige tnf-hæmmende antistoffer |
Country Status (23)
Country | Link |
---|---|
US (4) | US8673310B2 (da) |
EP (3) | EP3444274B1 (da) |
JP (4) | JP6100463B2 (da) |
KR (5) | KR20190133077A (da) |
CN (2) | CN107936117B (da) |
AU (1) | AU2009264564B2 (da) |
BR (1) | BRPI0914319B8 (da) |
CA (1) | CA2727992C (da) |
CL (1) | CL2010001543A1 (da) |
CY (1) | CY1123978T1 (da) |
DK (2) | DK2307457T4 (da) |
ES (2) | ES2861592T3 (da) |
HR (1) | HRP20210357T1 (da) |
HU (2) | HUE053548T2 (da) |
LT (1) | LT3444274T (da) |
MX (2) | MX2011000075A (da) |
PH (1) | PH12014501962B1 (da) |
PL (2) | PL3444274T3 (da) |
PT (2) | PT2307457T (da) |
RU (4) | RU2567100C2 (da) |
SI (2) | SI2307457T2 (da) |
WO (1) | WO2009155723A2 (da) |
ZA (2) | ZA201008593B (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE038432T2 (hu) | 2008-06-25 | 2018-10-29 | Esbatech Alcon Biomed Res Unit | Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával |
CN107936117B (zh) | 2008-06-25 | 2022-12-23 | 诺华股份有限公司 | 抑制TNFα的稳定和可溶的抗体 |
WO2010003268A2 (en) | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
AU2010217120B2 (en) | 2009-02-24 | 2014-11-20 | Novartis Ag | Methods for identifying immunobinders of cell-surface antigens |
KR101721187B1 (ko) * | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
RU2535033C2 (ru) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
AU2016277637B2 (en) * | 2010-10-22 | 2018-11-08 | Novartis Ag | Stable and soluble antibodies |
AR083495A1 (es) * | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
AU2013203189B2 (en) * | 2010-10-22 | 2014-12-11 | Novartis Ag | Stable and soluble antibodies |
EP2471554A1 (en) * | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
US20130344081A1 (en) * | 2011-03-07 | 2013-12-26 | The University Of Tokushima | Method of treating amyotrophic lateral sclerosis |
EP3431495A1 (en) * | 2011-10-20 | 2019-01-23 | ESBATech - a Novartis Company LLC | Stable multiple antigen-binding antibody |
CA2867910C (en) | 2012-03-20 | 2023-09-26 | Biogen Idec Ma Inc. | Jcv neutralizing antibodies |
RS58910B1 (sr) * | 2012-03-20 | 2019-08-30 | Biogen Ma Inc | Antitela koja neutrališu virus jcv |
CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
WO2014095808A1 (en) | 2012-12-17 | 2014-06-26 | Delenex Therapeutics Ag | Antibodies against il-1 beta |
CA2894918A1 (en) * | 2013-02-15 | 2014-08-21 | Esbatech - A Novartis Company Llc | Acceptor framework for cdr grafting |
CA2914829A1 (en) * | 2013-06-26 | 2014-12-31 | Numab Ag | Novel antibody frameworks |
CN106414498B (zh) * | 2014-03-26 | 2020-09-08 | 细胞药物瑞士股份公司 | TNF α的结合成员 |
CN105727285B (zh) * | 2014-12-10 | 2018-06-19 | 信达生物制药(苏州)有限公司 | 一种单克隆抗体在治疗神经退行性疾病中的应用 |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
ES2836349T3 (es) | 2016-03-17 | 2021-06-24 | Tillotts Pharma Ag | Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos |
CN109071649B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
WO2017158079A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | Anti-tnfalpha-antibodies and functional fragments thereof |
WO2017158101A1 (en) | 2016-03-17 | 2017-09-21 | Numab Innovation Ag | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
SI3219727T1 (sl) | 2016-03-17 | 2021-04-30 | Tillotts Pharma Ag | Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti |
US20190177407A1 (en) | 2016-06-20 | 2019-06-13 | Novartis Ag | Methods of treating dry eye disease using tnf alpha antagonists |
WO2018111328A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of tnf inhibitors at the site of gastrointestinal tract disease |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
EP3409688A1 (en) | 2017-05-31 | 2018-12-05 | Tillotts Pharma Ag | Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof |
EP3456739A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Use of anti-tnfalpha antibodies for treating wounds |
EP3456738A1 (en) * | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
EP3459527B1 (en) | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
EP3459529A1 (en) | 2017-09-20 | 2019-03-27 | Tillotts Pharma Ag | Preparation of sustained release solid dosage forms comprising antibodies by spray drying |
ES2938609T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
US20210179687A1 (en) * | 2017-11-07 | 2021-06-17 | The Board Of Regents Of The University Of Texas System | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
AR117707A1 (es) | 2018-12-18 | 2021-08-25 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
AU2020215795A1 (en) | 2019-01-31 | 2021-07-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof |
CA3164910A1 (en) | 2020-01-23 | 2021-07-29 | Young Chul Sung | Fusion protein comprising pd-l1 protein and use thereof |
WO2022174378A1 (zh) * | 2021-02-19 | 2022-08-25 | 骏运投资有限公司 | 痘苗病毒致炎兔皮提取物治疗神经***脱髓鞘疾病的用途 |
TW202321311A (zh) * | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | 與scFv等之連接子結合的抗體 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) * | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
EP0279582A3 (en) * | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US5013653A (en) * | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
JPH02500329A (ja) * | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
US5644034A (en) * | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
ES2159529T5 (es) * | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
US6905668B1 (en) | 1998-09-25 | 2005-06-14 | Tokyo Gas Company Limited | Diagnostic agents for pancreatic exocrine function |
US6470213B1 (en) * | 1999-03-30 | 2002-10-22 | Kenneth A. Alley | Implantable medical device |
EP2392596A3 (en) | 1999-12-28 | 2013-11-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
SG97908A1 (en) * | 2000-08-03 | 2003-08-20 | Inst Data Storage | A method and apparatus for load/unload testing of disk drives |
JP2006508638A (ja) * | 2002-05-22 | 2006-03-16 | エスバテック・アーゲー | 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 |
US20040086979A1 (en) * | 2002-08-15 | 2004-05-06 | Dongxiao Zhang | Humanized rabbit antibodies |
DE10314412A1 (de) | 2003-03-28 | 2004-10-14 | Genovac Ag | Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern |
US20050048578A1 (en) * | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
JP2007520991A (ja) | 2003-08-07 | 2007-08-02 | エピトミクス インコーポレーティッド | ウサギ単クローン抗体をヒト型化する方法 |
CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
WO2005049597A1 (ja) | 2003-11-20 | 2005-06-02 | Mitsubishi Gas Chemical Company, Inc. | 液状シクロヘキサントリカルボン酸無水物 |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
US20080003617A1 (en) | 2004-12-20 | 2008-01-03 | Xiaomin Fan | Methods for the identification and the isolation of epitope specific antibodies |
US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
PT2390267E (pt) | 2005-06-07 | 2013-07-16 | Esbatech A Novartis Co Llc | Anticorpos estáveis e solúveis que inibem tnf(alfa) |
NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US7429487B2 (en) * | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
GB0520436D0 (en) | 2005-10-07 | 2005-11-16 | Photobiotics Ltd | Biological materials and uses thereof |
US20100168393A1 (en) | 2005-10-11 | 2010-07-01 | Big Glucose Ltd. | Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
PL2013236T3 (pl) | 2006-04-28 | 2015-12-31 | Delenex Therapeutics Ag | Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK |
RS53168B (en) | 2006-05-30 | 2014-06-30 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
WO2008004834A1 (en) † | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
CN101505794B (zh) † | 2006-07-10 | 2013-09-04 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 穿过上皮和/或内皮层的scFV抗体 |
JP2010509369A (ja) | 2006-11-10 | 2010-03-25 | ジェネンテック インコーポレイテッド | 加齢黄斑変性症を処置するための方法 |
US8280711B2 (en) | 2007-03-12 | 2012-10-02 | ESBATech, an Alcon Biomedical Research Unit, LLC. | Sequence based engineering and optimization of single chain antibodies |
MX343879B (es) | 2007-05-21 | 2016-11-25 | Alderbio Holdings Llc | Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados. |
KR101530723B1 (ko) | 2007-06-25 | 2015-06-22 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화 |
JP5611820B2 (ja) | 2007-06-25 | 2014-10-22 | エスバテック − ア ノバルティスカンパニー エルエルシー | 抗体の修飾方法並びに改善された機能特性を有する修飾された抗体 |
DK2307454T3 (da) | 2008-06-25 | 2017-04-24 | Esbatech Alcon Biomed Res Unit | Stabile og opløselige antistoffer, som inhiberer VEGF |
ES2884117T3 (es) | 2008-06-25 | 2021-12-10 | Novartis Ag | Optimización de la solubilidad de inmunoaglutinantes |
HUE038432T2 (hu) | 2008-06-25 | 2018-10-29 | Esbatech Alcon Biomed Res Unit | Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával |
CN107936117B (zh) | 2008-06-25 | 2022-12-23 | 诺华股份有限公司 | 抑制TNFα的稳定和可溶的抗体 |
WO2010003268A2 (en) * | 2008-07-10 | 2010-01-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods and compositions for enhanced delivery of macromolecules |
AU2010217120B2 (en) * | 2009-02-24 | 2014-11-20 | Novartis Ag | Methods for identifying immunobinders of cell-surface antigens |
KR101721187B1 (ko) * | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
CN106414498B (zh) * | 2014-03-26 | 2020-09-08 | 细胞药物瑞士股份公司 | TNF α的结合成员 |
TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
WO2017189959A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3091096A1 (en) | 2018-03-16 | 2019-09-19 | Novartis Ag | Methods for treating ocular diseases |
AR117707A1 (es) | 2018-12-18 | 2021-08-25 | Novartis Ag | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
-
2009
- 2009-06-25 CN CN201710511379.6A patent/CN107936117B/zh active Active
- 2009-06-25 WO PCT/CH2009/000219 patent/WO2009155723A2/en active Application Filing
- 2009-06-25 KR KR1020197034623A patent/KR20190133077A/ko active Application Filing
- 2009-06-25 CN CN200980123825XA patent/CN102076716A/zh active Pending
- 2009-06-25 PT PT09768692T patent/PT2307457T/pt unknown
- 2009-06-25 EP EP18177227.8A patent/EP3444274B1/en active Active
- 2009-06-25 KR KR1020187024302A patent/KR102050040B1/ko active IP Right Grant
- 2009-06-25 PT PT181772278T patent/PT3444274T/pt unknown
- 2009-06-25 MX MX2011000075A patent/MX2011000075A/es active IP Right Grant
- 2009-06-25 SI SI200931875T patent/SI2307457T2/sl unknown
- 2009-06-25 EP EP09768692.7A patent/EP2307457B2/en active Active
- 2009-06-25 EP EP20215926.5A patent/EP3858854A1/en not_active Withdrawn
- 2009-06-25 PL PL18177227T patent/PL3444274T3/pl unknown
- 2009-06-25 KR KR1020117001793A patent/KR101773904B1/ko active IP Right Grant
- 2009-06-25 US US13/000,345 patent/US8673310B2/en active Active
- 2009-06-25 SI SI200932116T patent/SI3444274T1/sl unknown
- 2009-06-25 HU HUE18177227A patent/HUE053548T2/hu unknown
- 2009-06-25 DK DK09768692.7T patent/DK2307457T4/da active
- 2009-06-25 KR KR1020167029809A patent/KR101893010B1/ko active IP Right Grant
- 2009-06-25 RU RU2011102579/10A patent/RU2567100C2/ru active
- 2009-06-25 RU RU2015138696A patent/RU2653753C1/ru active
- 2009-06-25 LT LTEP18177227.8T patent/LT3444274T/lt unknown
- 2009-06-25 CA CA2727992A patent/CA2727992C/en active Active
- 2009-06-25 MX MX2014003709A patent/MX345039B/es unknown
- 2009-06-25 JP JP2011515048A patent/JP6100463B2/ja active Active
- 2009-06-25 BR BRPI0914319A patent/BRPI0914319B8/pt active IP Right Grant
- 2009-06-25 AU AU2009264564A patent/AU2009264564B2/en active Active
- 2009-06-25 PL PL09768692.7T patent/PL2307457T5/pl unknown
- 2009-06-25 DK DK18177227.8T patent/DK3444274T3/da active
- 2009-06-25 ES ES18177227T patent/ES2861592T3/es active Active
- 2009-06-25 ES ES09768692T patent/ES2687259T5/es active Active
- 2009-06-25 HU HUE09768692A patent/HUE039692T2/hu unknown
- 2009-06-25 KR KR1020217015785A patent/KR20210065201A/ko active Application Filing
-
2010
- 2010-11-30 ZA ZA2010/08593A patent/ZA201008593B/en unknown
- 2010-12-23 CL CL2010001543A patent/CL2010001543A1/es unknown
-
2013
- 2013-11-21 ZA ZA2013/08787A patent/ZA201308787B/en unknown
- 2013-12-19 US US14/134,779 patent/US9422366B2/en active Active
-
2014
- 2014-09-01 PH PH12014501962A patent/PH12014501962B1/en unknown
-
2015
- 2015-01-23 JP JP2015010886A patent/JP2015083607A/ja active Pending
-
2016
- 2016-05-18 US US15/157,641 patent/US10100111B2/en active Active
- 2016-12-16 JP JP2016244030A patent/JP2017051201A/ja not_active Withdrawn
-
2018
- 2018-04-11 RU RU2018113177A patent/RU2678120C1/ru active
- 2018-09-12 US US16/128,691 patent/US11578123B2/en active Active
- 2018-12-27 RU RU2018146937A patent/RU2704838C1/ru active
-
2019
- 2019-08-26 JP JP2019153608A patent/JP2019195342A/ja active Pending
-
2021
- 2021-03-02 HR HRP20210357TT patent/HRP20210357T1/hr unknown
- 2021-03-18 CY CY20211100234T patent/CY1123978T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3444274T3 (da) | Stabile og opløselige antistoffer, der hæmmer TNF | |
DK3216803T3 (da) | Stabile og opløselige antistoffer, der hæmmer vegf | |
DK2390267T3 (da) | Stabile og opløselige antistoffer, der hæmmer TNF(alfa) | |
DK3338799T3 (da) | Antistoffer til il-6 og anvendelse deraf | |
BRPI0911989A2 (pt) | uniões micélicas | |
DK3091034T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
DK2337568T3 (da) | Fremgangsmåder og midler til blødvævsteknologi | |
DK2147315T3 (da) | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK2376791T3 (da) | Afstandsindretning og fastgørelsesindretning med afstandsindretning | |
DK2370461T3 (da) | Glucagonanaloger | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
BRPI0909657A2 (pt) | dispositivo espaçador intersomático expansível | |
DK2152748T3 (da) | Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3103478T3 (da) | Stabiliserede fibronektin-domænesammensætninger, fremgangsmåder og anvendelser | |
DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
BRPI0907231A2 (pt) | pirrolpirimidinas e pirrolpiridinas | |
DK2252633T3 (da) | Anti-TrkA antistoffer og derivater deraf | |
DK3266367T3 (da) | Systemer og fremgangsmåder til billeddannelse ved anvendelse af absorption | |
DK2270818T3 (da) | Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten | |
DK2281006T3 (da) | Tværbindingsmidler og anvendelser deraf | |
DK3812360T3 (da) | Monochlortrifluorpropen forbindelser og sammensætninger og metoder, der anvender dem | |
DK2388266T3 (da) | Fusionsmolekyler og IL-15-varianter | |
BRPI0918958A2 (pt) | dispositivo móvel, e, método | |
DK2328931T3 (da) | Selektive anti-hepcidin-25-antistoffer og anvendelser deraf |